
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded troche containing estriol, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing estriol is listed. Products containing it are filed in the directory as over-the-counter monograph drugs, unapproved drugs and homeopathic products, in cream and spray forms. None of the listed products containing estriol is in troche form.
Bases for this dose form differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Estriol is a naturally occurring estrogen hormone, available only by compounding in the United States, commonly prepared as vaginal creams, suppositories and topical creams.
Estriol is one of the three main estrogens the human body makes, alongside estradiol and estrone. It is produced in large amounts during pregnancy and is considered a weak, short-acting estrogen compared with estradiol. Like other estrogens, it acts by binding estrogen receptors in responsive tissues such as the vagina, uterus and breast. There is no FDA-approved drug product containing estriol in the United States; FDA has stated that estriol is not a component of any FDA-approved drug. Estriol is the subject of a USP monograph, which is one of the ways a bulk drug substance can qualify for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act.
Because no manufactured product exists, every estriol preparation is compounded, alone or combined with estradiol in one vehicle. Compounded estriol preparations are not FDA-approved, have not been reviewed by FDA for safety, effectiveness or quality, and require a prescription.
Because there is no manufactured estriol product, there is no FDA label for estriol itself. FDA-approved estrogen products such as Estrace estradiol vaginal cream carry a boxed warning for endometrial cancer, cardiovascular disorders (stroke, heart attack, blood clots), breast cancer and probable dementia, and state that estrogens should be used at the lowest dose that relieves symptoms, for the shortest time. Federal law exempts compounded drugs from this labeling, but the warnings describe the estrogen class. Estrogens should not be used by anyone with undiagnosed vaginal bleeding, current or past breast cancer or other estrogen-dependent cancer, a history of blood clots, stroke or heart attack, liver disease, or known pregnancy. Drugs that affect the CYP3A4 enzyme, including St. John's wort, rifampin, ketoconazole, clarithromycin and grapefruit juice, can change estrogen levels, and vaginal creams may weaken latex condoms. The Estrace label states estrogens should not be used during lactation because they reduce milk quantity and quality and pass into milk. If you have unexpected bleeding, breast changes, leg swelling, chest pain or sudden headache, contact your prescriber or pharmacist promptly.
Estriol (E3) is an endogenous C18 estrogen with lower estrogen receptor affinity and shorter receptor occupancy than estradiol, hence its characterization as a weak, short-acting agonist. It binds sex hormone binding globulin less avidly than other estrogens, undergoes extensive first-pass conjugation after oral administration, and has less enterohepatic recirculation than estradiol or estrone. Vaginal administration bypasses first-pass metabolism; in older pharmacokinetic work intravaginal doses produced serum levels comparable to tenfold larger oral doses. Compounded preparations are not routinely assessed for bioavailability.
There is no labeled indication, because no FDA-approved estriol product exists. Prescribers have ordered compounded vaginal estriol for vulvovaginal atrophy and genitourinary symptoms of menopause, and estriol with estradiol (so-called Bi-est) as topical hormone therapy. A 2022 meta-analysis found compounded estriol and estradiol have the fewest available trials, and the 2020 NASEM review commissioned by FDA concluded there is a lack of rigorous evidence of safety and effectiveness for compounded bioidentical hormones (NASEM, The Clinical Utility of Compounded Bioidentical Hormone Therapy, 2020). Older reviews report endometrial proliferative changes with continuous higher-dose or divided-dose estriol, whereas intravaginal estriol biopsies remained atrophic. Dose, frequency and whether to add a progestogen in a patient with a uterus are per prescriber. Monitoring follows estrogen class labeling: unexplained bleeding, breast examination, thromboembolic symptoms. Estriol is not a controlled substance.
Wash and dry your hands. Place the troche between your cheek and gum or under your tongue, as your label directs, and let it dissolve. Do not chew or swallow it whole unless told to. Dissolving can take up to 30 minutes. Follow your label about eating or drinking around the dose.
Troches are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in the closed container in a cool, dry place at room temperature, away from heat so they do not soften, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 troche between cheek and gum and let slowly dissolve